AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
16 Novembro 2023 - 9:00AM
Business Wire
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T
cell immunotherapy company, today announced that Diana Brainard,
M.D., Chief Executive Officer, will participate in a fireside chat
at the Piper Sandler 35th Annual Healthcare Conference in New York
City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.
A live webcast and archived replay of the presentation will be
available on the Investors & Press section of the AlloVir
website at https://ir.allovir.com.
About AlloVir
AlloVir is a leading late-clinical stage cell therapy company
focused on restoring natural immunity against life-threatening
viral diseases in pediatric and adult patients with weakened immune
systems. The company's innovative and proprietary technology
platform leverages off-the-shelf, allogeneic, single- and
multi-virus-specific T cells for patients with T cell deficiencies
who are at risk from the life-threatening consequences of viral
diseases. AlloVir's technology and manufacturing process enable the
potential for the treatment and prevention of a spectrum of
devastating viruses with each single allogeneic cell therapy. The
company is advancing multiple mid- and late-stage clinical trials
across its product portfolio. For more information, visit
www.allovir.com or follow us on Twitter/X or LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231116711808/en/
Media and Investor: ir@allovir.com
AlloVir (NASDAQ:ALVR)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
AlloVir (NASDAQ:ALVR)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
